Initial Therapeutics
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $75M
Overview
Developing RNA-targeted therapeutics for severe neurological and rare genetic diseases.
NeuroscienceRare Disease
Technology Platform
A platform for discovering small molecules that selectively bind to disease-causing RNA structures to modulate their function.
Funding History
1Total raised:$75M
Venture$75M
Opportunities
Potential to create first-in-class medicines for devastating diseases with no current treatment options.
Risk Factors
High technical risk associated with the novel and unproven approach of targeting RNA with small molecules in humans.
Competitive Landscape
Operates in a pioneering but risky segment, with competition from companies like Arrakis Therapeutics and Skyhawk Therapeutics.